A recent scientific study has revealed that a bat-borne virus unrelated to Nipah has been infecting humans in Bangladesh, raising new questions about zoonotic disease surveillance in South Asia. While ...

A mystery illness in Bangladesh, initially thought to be a Nipah infection outbreak, is actually due to another emerging and potentially deadly bat-borne virus, scientists warned in a new study.

Researchers in Bangladesh have identified a bat-borne virus, Pteropine orthoreovirus, in patients who were initially suspected of having Nipah virus but tested negative. All had recently consumed raw ...

Under the priority review voucher (PRV) rare disease program, which began in 2012, a sponsor files for the FDA’s Rare Pediatric Drug Designation. Then, if that drug is approved, the FDA grants a PRV, ...

Even in the era of the FDA's Commissioner's National Priority Voucher (CNPV) program, Jazz Pharmaceuticals is showing that traditional priority review vouchers (PRVs) can catch a pretty penny. In fact ...

Are you picking the right automation technology for your operation? Choosing the wrong automation type, either pneumatic or electric, can be costly. This decision can lead to higher energy bills, ...

In today’s homebuilding and plumbing environments, water conservation isn’t just a sustainability goal—it’s a business and liability imperative. From fluctuating municipal water supplies to the risk ...

If you enjoyed this article, I’d like to ask for your support. Scientific American has served as an advocate for science and industry for 180 years, and right now may be the most critical moment in ...

After gaining FDA approval for Miplyffa ® (arimoclomol) as the first-ever therapy indicated to treat Niemann-Pick disease type C (NPC), Zevra Therapeutics has cashed in on the regulatory win by ...

Zevra Therapeutics announces a $150 million sale of its Rare Pediatric Disease Priority Review Voucher to enhance its capital. Zevra Therapeutics, Inc. has announced the sale of its Rare Pediatric ...